Carolina Wealth Advisors LLC Has $756,000 Holdings in The Clorox Company (NYSE:CLX)

Carolina Wealth Advisors LLC grew its position in The Clorox Company (NYSE:CLX - Free Report) by 290.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,133 shares of the company's stock after purchasing an additional 3,818 shares during the quarter. Carolina Wealth Advisors LLC's holdings in Clorox were worth $756,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Norges Bank purchased a new stake in Clorox in the fourth quarter valued at $259,041,000. FMR LLC boosted its holdings in Clorox by 75.4% in the 4th quarter. FMR LLC now owns 1,361,758 shares of the company's stock valued at $221,163,000 after purchasing an additional 585,526 shares in the last quarter. Marshall Wace LLP grew its holdings in Clorox by 549.8% during the fourth quarter. Marshall Wace LLP now owns 542,726 shares of the company's stock worth $88,144,000 after acquiring an additional 459,203 shares during the period. ExodusPoint Capital Management LP increased its holdings in shares of Clorox by 187.9% in the 4th quarter. ExodusPoint Capital Management LP now owns 698,900 shares of the company's stock valued at $113,508,000 after purchasing an additional 456,114 shares in the last quarter. Finally, Man Group plc lifted its position in shares of Clorox by 154.6% during the 4th quarter. Man Group plc now owns 570,503 shares of the company's stock valued at $92,655,000 after acquiring an additional 346,449 shares during the period. 78.53% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Clorox

In related news, Director Pierre R. Breber purchased 4,000 shares of Clorox stock in a transaction dated Wednesday, May 7th. The stock was acquired at an average cost of $136.57 per share, with a total value of $546,280.00. Following the completion of the transaction, the director directly owned 4,000 shares of the company's stock, valued at $546,280. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.57% of the stock is currently owned by company insiders.

Clorox Price Performance

Clorox stock traded up $3.42 during trading hours on Tuesday, hitting $123.49. 2,320,233 shares of the company traded hands, compared to its average volume of 1,391,572. The Clorox Company has a 1-year low of $117.35 and a 1-year high of $171.37. The company has a quick ratio of 0.44, a current ratio of 0.74 and a debt-to-equity ratio of 13.07. The firm has a market cap of $15.22 billion, a P/E ratio of 22.17, a P/E/G ratio of 2.70 and a beta of 0.54. The firm's 50-day simple moving average is $130.83 and its two-hundred day simple moving average is $144.69.

Clorox (NYSE:CLX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.12). The business had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. Clorox had a return on equity of 324.23% and a net margin of 9.89%. The business's revenue for the quarter was down 8.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.71 EPS. As a group, analysts forecast that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on CLX. Wells Fargo & Company dropped their price target on Clorox from $145.00 to $142.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Citigroup dropped their target price on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating for the company in a report on Monday, April 14th. Evercore ISI set a $140.00 target price on Clorox and gave the company an "underperform" rating in a report on Tuesday, May 6th. Jefferies Financial Group cut their price target on Clorox from $167.00 to $145.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Finally, UBS Group dropped their price objective on Clorox from $176.00 to $154.00 and set a "neutral" rating for the company in a research report on Thursday, April 17th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, Clorox has an average rating of "Hold" and a consensus target price of $149.50.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.